Webster Bank Cut Amazon Com (AMZN) Position By $421,879; Orbimed Advisors Upped Clovis Oncology (CLVS) Holding

February 23, 2018 - By Henry Gaston

Orbimed Advisors Llc increased Clovis Oncology Inc (CLVS) stake by 13.51% reported in 2017Q3 SEC filing. Orbimed Advisors Llc acquired 284,300 shares as Clovis Oncology Inc (CLVS)’s stock declined 20.61%. The Orbimed Advisors Llc holds 2.39 million shares with $196.83 million value, up from 2.10M last quarter. Clovis Oncology Inc now has $2.94B valuation. The stock increased 9.01% or $4.95 during the last trading session, reaching $59.88. About 3.58 million shares traded or 180.33% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since February 23, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Webster Bank decreased Amazon Com Inc (AMZN) stake by 5.36% reported in 2017Q3 SEC filing. Webster Bank sold 439 shares as Amazon Com Inc (AMZN)’s stock rose 13.58%. The Webster Bank holds 7,751 shares with $7.45M value, down from 8,190 last quarter. Amazon Com Inc now has $719.06 billion valuation. The stock increased 0.16% or $2.42 during the last trading session, reaching $1485.34. About 4.86M shares traded. Amazon.com, Inc. (NASDAQ:AMZN) has risen 37.41% since February 23, 2017 and is uptrending. It has outperformed by 20.71% the S&P500.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 59 analyst reports since September 10, 2015 according to SRatingsIntel. The stock has “Buy” rating by Leerink Swann on Monday, February 5. As per Wednesday, September 21, the company rating was maintained by Stifel Nicolaus. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Hold” rating by WallachBeth Capital on Tuesday, November 17. The stock has “Overweight” rating by JP Morgan on Wednesday, May 17. On Monday, July 31 the stock rating was maintained by Oppenheimer with “Hold”. Suntrust Robinson initiated the stock with “Buy” rating in Friday, August 5 report. Stifel Nicolaus maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Monday, September 11. Stifel Nicolaus has “Buy” rating and $125.0 target. J.P. Morgan maintained the shares of CLVS in report on Thursday, June 1 with “Buy” rating. Bank of America maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, August 2 with “Buy” rating. Chardan Capital Markets upgraded the shares of CLVS in report on Tuesday, December 20 to “Neutral” rating.

Investors sentiment decreased to 1.44 in Q3 2017. Its down 0.37, from 1.81 in 2017Q2. It dropped, as 48 investors sold CLVS shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. Wells Fargo & Co Mn invested in 0.01% or 273,094 shares. Hbk Invs Lp owns 26,664 shares. Federated Investors Incorporated Pa holds 10,000 shares or 0% of its portfolio. 40,391 are held by Dimensional Fund Advisors L P. Kennedy Capital Incorporated stated it has 0.04% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Smith Asset Management Group Inc Lp invested 0.02% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Tocqueville Asset Mngmt Limited Partnership reported 83,135 shares. Moreover, Hudson Bay LP has 0.08% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). Nj State Employees Deferred Compensation Plan holds 0.13% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 9,000 shares. Invesco Limited holds 0.01% or 480,582 shares. Plante Moran Ltd Liability Com stated it has 57 shares. Alliancebernstein Limited Partnership holds 961,777 shares or 0.06% of its portfolio. Jasper Ridge Prns LP stated it has 0.04% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Putnam Investments Lc accumulated 827,155 shares. Palo Alto Investors Ltd Liability Company holds 3.33 million shares.

Orbimed Advisors Llc decreased Newlink Genetics Corp (Call) (NASDAQ:NLNK) stake by 1.80 million shares to 50,000 valued at $509,000 in 2017Q3. It also reduced Bristol Myers Squibb Co (Call) (NYSE:BMY) stake by 724,700 shares and now owns 150,000 shares. Boston Scientific Corp (NYSE:BSX) was reduced too.

Since September 15, 2017, it had 0 insider buys, and 6 selling transactions for $1.29 million activity. IVERS-READ GILLIAN C also sold $253,620 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) on Monday, October 16. 4,500 Clovis Oncology, Inc. (NASDAQ:CLVS) shares with value of $292,365 were sold by SPICKSCHEN THORLEF.

Among 53 analysts covering Amazon.com (NASDAQ:AMZN), 50 have Buy rating, 0 Sell and 3 Hold. Therefore 94% are positive. Amazon.com had 274 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, August 25 by Needham. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has “Outperform” rating given on Friday, July 29 by CLSA. The firm earned “Buy” rating on Friday, July 24 by B. Riley & Co. The rating was maintained by SunTrust on Monday, October 2 with “Buy”. The firm earned “Buy” rating on Tuesday, May 3 by Nomura. The stock of Amazon.com, Inc. (NASDAQ:AMZN) earned “Buy” rating by Canaccord Genuity on Friday, July 29. The firm has “Buy” rating given on Monday, July 17 by UBS. M Partners initiated Amazon.com, Inc. (NASDAQ:AMZN) rating on Tuesday, December 15. M Partners has “Buy” rating and $800.0 target. As per Friday, September 30, the company rating was initiated by Guggenheim. Pacific Crest maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, July 29. Pacific Crest has “Overweight” rating and $847 target.

Webster Bank increased Vanguard Etf/Usa (VCIT) stake by 4,744 shares to 5,059 valued at $445,000 in 2017Q3. It also upped Blackrock Fund Advisors (EFA) stake by 7,041 shares and now owns 112,872 shares. Vanguard Intl Equi (VGK) was raised too.

Analysts await Amazon.com, Inc. (NASDAQ:AMZN) to report earnings on April, 26. They expect $1.19 earnings per share, down 19.59% or $0.29 from last year’s $1.48 per share. AMZN’s profit will be $576.09M for 312.05 P/E if the $1.19 EPS becomes a reality. After $2.16 actual earnings per share reported by Amazon.com, Inc. for the previous quarter, Wall Street now forecasts -44.91% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts